HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A2482 Apitegromab (Anti-GDF8 / Myostatin) Apitegromab (Anti-GDF8 / Myostatin) is a fully human monoclonal antibody that binds to human promyostatin and latent myostatin with a high degree of specificity, without binding to mature myostatin and other closely related growth factors. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy. MW: 145.5 KD. Human IgG4SP
A2483 Ponsegromab (Anti-GDF15 / MIC-1) Ponsegromab (Anti-GDF15 / MIC-1) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers. MW: 145.5 KD. Human IgG1
A2484 Ecromeximab (Anti-GD3) Ecromeximab (Anti-GD3) is a human-mouse chimeric IgG1 monoclonal antibody with potential antineoplastic activity that targets ganglioside GD3, a surface antigen expressed on many malignant melanoma cells. It binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. MW: 145.5 KD. Human IgG1
A2485 Dinutuximab (Anti-GD2) Dinutuximab (Anti-GD2) is a chimeric mouse/human monoclonal antibody that targets ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. It has potential antineoplastic activity. MW: 145.5 KD. Human IgG1
A2486 Naxitamab (Anti-GD2) Naxitamab (Anti-GD2) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers. MW: 145.5 KD. Human IgG1
A2487 Volagidemab (Anti-GCGR) Volagidemab (Anti-GCGR) is an antagonistic monoclonal antibody (mAb) that targets glucagon receptor (GCGR). Volagidemab can be used in the research of type 1 diabetes (T1D). MW: 145.5 KD. Human IgG2SA
A2488 Tabituximab (Anti-FZD10) Tabituximab (Anti-FZD10) is a humanized monoclonal antibody that targets frizzled class receptor 10 (FZD10). MW: 145.5 KD. Human IgG1
A2489 Vantictumab (Anti-FZD) Vantictumab (Anti-FZD) is a monoclonal antibody targeting the Wnt signaling pathway with potential antineoplastic activity. Vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This results in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. MW: 145.5 KD. Human IgG2SA
A2490 Anti-Fucosyl GM1 Anti-Fucosyl GM1 is a antibody that recognizes and targets the fucosyl form of ganglioside GM1. MW: 145.5 KD. Human IgG1
A2491 Mirvetuximab (Anti-FOLR1) Mirvetuximab (Anti-FOLR1) is a monoclonal antibody targeting FOLR1 (folate receptor 1). Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). MW: 145.2 KD Human IgG1
A2492 Farletuzumab (Anti-FOLR1) Farletuzumab (Anti-FOLR1) is a humanized monoclonal antibody with high affinity for FRα. It is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. MW: 144.12 KD Human IgG1
A2494 Anti-FGFR4 / CD334 Anti-FGFR4 / CD334 (U3-1784) is a human monoclonal antibody targeting FGFR4 (human fibroblast growth factor receptor 4), with potential antineoplastic activity. It blocks activation of FGFR4, which inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. MW: 145.5 KD. Human IgG1
A2495 Vofatamab (Anti-FGFR3 / CD333) Vofatamab (Anti-FGFR3 / CD333) is a monoclonal antibody targeting FGFR3. Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). MW: 145.5 KD. Human IgG1
A2496 Anti-FGFR3 / CD333 Anti-FGFR3 / CD333 (LY3076226) is a human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor type 3). MW: 145.5 KD. Human IgG1
A2499 Burosumab (Anti-FGF23) Burosumab (Anti-FGF23) is a neutralizing antibody, targeting human fibroblast growth factor 23 (FGF23). It can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. MW: 145.5 KD. Human IgG1
A2500 Rozanolixizumab (Anti-FcRn (FCGRT & B2M)) Rozanolixizumab (Anti-FcRn (FCGRT & B2M)) is a high-affinity humanized monoclonal antibody, targeting human neonatal Fc receptor (FcRn) and is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases. MW: 150 KD. Human IgG4SP
A2501 Lumiliximab (Anti-FceR2 / CD23) Lumiliximab (Anti-FceR2 / CD23) is a monoclonal antibody targeting CD23, that inhibits allergen-induced responses. MW: 145.5 KD. Human IgG1
A2502 Emicizumab (Anti-F9 / Factor IX) Emicizumab (Anti-F9 / Factor IX) is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research. MW: 145.5 KD. Human IgG4SP
A2503 Garadacimab (Anti-F12 / Factor XII) Garadacimab (Anti-F12 / Factor XII) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research. MW: 145.5 KD. Human IgG4SP
A2504 Osocimab (Anti-F11 / Factor XI) Osocimab (Anti-F11 / Factor XI) is an antibody targeting Factor FXI. FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects. MW: 145.5 KD. Human IgG1